In a recent study published in Helicobacter journal, comprising of 163 patients with Helicobacter pylori infection, the treatment success of vonoprazan and amoxicillin (VA) dual therapy was associated with the small physique of patients.

This study by Hiroyuki Eto et al. investigated upon the clinical aspects linked with Helicobacter pylori eradication rate with VA-dual therapy.

The patients having Helicobacter pylori on VA-dual (Vonoprazan 20 mg and Amoxicillin 750 mg both two times a day for 7 days) therapy were recruited. The clinical aspects under consideration were: age, gender, height, weight, body mass index (BMI), body surface area (BSA), earlier records of initial gastric carcinoma and ulcer, co-morbidity of cirrhosis, smoking and alcohol intake, frequent use of PPIs, and simultaneous use of medicines that are substrates of cytochrome P450 (CYP) 3A4. The link between post-eradication adverse events and clinical factors was assessed.

The effectiveness of H. pylori eradication rate was linked with a lesser BSA (90.8% rate in patients with BSA less than 1.723 versus 79.6% rate in those with BSA greater than equal to 1.723). Frequency of adverse events was greater in women (40.0%) as compared to men (19.4%). Considering the body size of the patients can help to find the effectiveness of VA therapy in cases of Helicobacter pylori.